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Diabetes mellitus is associated with an increased risk of cardiovascular disease \[[@CR1]\]. Endothelial dysfunction is considered to be the primary cause in the pathogenesis of vascular disease in diabetes \[[@CR1]\]. Although the mechanism whereby diabetes leads to endothelial dysfunction is incompletely understood, a common feature of endothelial dysfunction is a decreased bioavailability of endothelium-derived nitric oxide (NO) and, as a consequence, impaired endothelium-dependent vasorelaxation \[[@CR1]\]. Several studies have demonstrated impaired endothelium-dependent vasorelaxation in diabetic patients \[[@CR2], [@CR3]\] and in animal models of diabetes \[[@CR4], [@CR5]\].

One hypothesis of how hyperglycaemia leads to endothelial dysfunction and vascular complications is the formation of AGEs \[[@CR6]\]. AGEs are a heterogeneous family of non-enzymatically modified proteins formed by carbohydrates, which are increased in patients with diabetes \[[@CR7]--[@CR9]\]. The mechanisms by which AGEs contribute to vascular complications are multiple, including their interaction with the receptor for AGE (RAGE), the formation of cross-links in basal membranes and intracellular accumulation of glycated proteins \[[@CR6]\]. Although it has been demonstrated that AGEs are associated with impaired endothelium-dependent vasorelaxation in type 2 diabetes \[[@CR10]\] and can reduce endothelium-dependent vasorelaxation \[[@CR11]\], it is not known which specific AGEs are the culprits or which pathways are involved.

It is now apparent that especially intracellular sugars and their derivatives can participate in glycation and AGE formation \[[@CR12]\]. The reactive dicarbonyl methylglyoxal has received considerable attention as the most reactive AGE precursor in endothelial cells \[[@CR13]\]. Methylglyoxal is formed non-enzymatically by dephosphorylation of triose phosphates and is efficiently catabolised to [d]{.smallcaps}-lactate by the glyoxalase (GLO) pathway, consisting of GLO-I, GLO-II and the co-factor glutathione \[[@CR14]\]. Methylglyoxal primarily reacts with arginine residues to form the major adduct 5-hydro-5-methylimidazolone (MG-H1) and with lysine to form *N*^ε^-(1-carboxyethyl)lysine (CEL) \[[@CR15], [@CR16]\]. Plasma methylglyoxal levels are significantly increased in diabetic patients \[[@CR17]\] and in endothelial cells by hyperglycaemia \[[@CR18]\]. The importance of methylglyoxal and methylglyoxal-derived AGEs for the development of diabetic vascular complications and hypertension has only recently been recognised. Recent studies have demonstrated that increased methylglyoxal-derived AGE levels in diabetic patients are associated with diabetic complications such as nephropathy \[[@CR19]\] and retinopathy \[[@CR20]\], and with diabetes-related vascular disorders such as hypertension \[[@CR21]--[@CR25]\]. As a major precursor of AGE formation, methylglyoxal can influence multiple aspects of cellular biology in diabetes \[[@CR26]\]. Methylglyoxal targets specific mitochondrial proteins accompanied by an increase in the formation of reactive oxygen species (ROS) \[[@CR27]\]. Since ROS production by mitochondria is responsible for major mechanisms involved in diabetic complications, methylglyoxal-induced ROS production may be an initial event in the pathogenesis of vascular complications.

We hypothesised that accumulation of methylglyoxal can lead to endothelial dysfunction by ROS formation and therefore evaluated the effect of hyperglycaemia, methylglyoxal and methylglyoxal-modified albumin on endothelium-dependent NO-mediated vasorelaxation, a measure of endothelial function, and tested the involvement of oxidative stress therein.

Methods {#Sec2}
=======

**Animals** All animal studies were carried out in accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All experiments involving rats were reviewed and approved by the Ethics Committee for animal care and use of Maastricht University, the Netherlands.

*GLO-I* (also known as *GLO1*) transgenic rats were obtained from T. Miyata \[[@CR28]\]. Rat genomic DNA extracted from tail tissue was used to detect the transgene by PCR using specific primers for *GLO-I* or pBsCAG-2 vector. Primers for cytomegalovirus enhancer, sense (5′-GTC GAC ATT GAT TAT TGA CTA G-3′) and antisense (5′-CCA TAA GGT CAT GTA CTG-3′), amplified a 350 bp fragment. Primers for the fragment containing human *GLO-I* gene and 3′ junction of vector, sense (5′-GTA GTG TGG GTG ACT CCT CCG TTC CTT GGG-3′) and antisense (5′-TCG AGG GAT CTT CAT AAG AGA AGA G-3′), amplified a 1,200 bp fragment. PCR amplification was carried out with an initial denaturation at 95°C for 5 min, followed by 35 cycles of 95°C at 30 s, 55°C or 58°C at 30 s and 72°C at 30 or 75 s.

Wild-type rats (*n* = 9) and transgenic *GLO-I* rats (*n* = 8) were made diabetic by intravenous injection of streptozotocin (65 mg/kg body weight) in the tail vein. Weight- and age-matched control rats (*n* = 9) and transgenic *GLO-I* rats (*n* = 8) were not injected. Streptozotocin resulted in a fivefold increase of blood glucose levels, irrespective of *GLO-I* overexpression.

**Methylglyoxal-modified albumin preparation and characterisation** Methylglyoxal was purchased from Sigma Aldrich (St Louis, MO, USA) and methylglyoxal-modified albumin was prepared by incubating human albumin (Cealb; Sanquin, Amsterdam, the Netherlands) in a phosphate buffer (0.2 mol/l), pH 7.8, with 0.5 or 10 mmol/l methylglyoxal for 2, 4 or 8 days. After incubation, the preparations were extensively dialysed against PBS at 4°C with three changes of solution. The reagents were divided into aliquots and stored at 20°C. *N*^*ε*^-(carboxymethyl)lysine (CML), CEL and MG-H1 were measured by ultra-performance liquid chromatography (tandem) mass spectrometry UPLC-MSMS as previously described \[[@CR29]\].

**Isometric tension measurements** Healthy adult male wild-type Wistar rats or adult Wistar rats with human *GLO-I* overexpression (*GLO-I* TG) (300--450 g) were killed by CO~2~ inhalation. Second-order mesenteric arteries were isolated and then mounted in a myograph organ bath model (610 M; Danish Myotechnology by J. P. Trading, Aarhus, Denmark) with two steel 40 μm wires inserted through the lumen of the segments. NO-mediated effects were selectively investigated using acetylcholine (0.01--10.00 μmol/l) and sodium nitroprusside (SNP; 0.01--10.00 μmol/l) during contraction with 65 mmol/l K^+^ (which blocks endothelium-derived hyperpolarising factors), following preincubation with the prostaglandin blocker indometacin (10 μmol/l) (details, see [Electronic supplementary material](#MOESM1){ref-type=""} \[ESM\]).

**Endothelial cell culture** In the in vitro experiments we used ECRF24 cells, which are derived from human umbilical vein endothelial cells, immortalised using an amphotrophic, replication-deficient retrovirus containing the *E6*/*E7* genes of human papilloma virus \[[@CR30]\]. Most of the experiments were also performed with HUVEC and showed similar results to those with ECRF24. ECRF24 cells were cultured on fibronectine-coated 75 cm^2^ flasks and maintained at 37°C in 5% CO~2~. Culture medium consisted of M199 (with Na~2~HCO~3~ and glutamine; Lonza, Basel, Switzerland) containing 20% (vol./vol.) heat-inactivated fetal calf serum (HyClone, Logan, UT, USA), 2 mmol/l glutamine (Invitrogen, San Diego, CA, USA), 100 U/ml penicillin (Invitrogen), 100 μg/ml streptomycin (Invitrogen), 50 µg/ml endothelial cell growth factor (Sigma Aldrich) and 5 U/ml heparin (Leo Pharma, Breda, the Netherlands).

**Immunohistochemistry** For immunohistochemistry, arteries were fixed with phosphate-buffered (pH 7.4) formaldehyde (4%, vol./vol.) for 30 min at 37°C at the end of the myograph experiments. Subsequently, arteries were transferred to 70% (vol./vol.) ethanol embedded in paraffin and processed for histological examination. An anti MG-H1 antibody was used to detect the major methylglyoxal-adduct MG-H1 and a polyclonal nitrotyrosine antibody (Calbiochem, San Diego, CA, USA) was used for detection of peroxynitrite formation.

**Immunofluorescence** ECRF24 cells were seeded on chamber slides (Lab-Tek II; Nunc, Rochester, NY, USA), fixed with paraformaldehyde (4%, wt/vol.) and permeabilised with Triton X-100 (0.1%, vol./vol.). Subsequently mouse anti-MG-H1 IgG (1:5000) was used as the primary antibody and FITC-conjugated anti-mouse IgG (1:30; Dako, Glostrup, Denmark) was used as the secondary antibody. Localisation was visualised with a confocal microscope (MRC600; Bio-Rad Laboratories, Hemel Hempstead, UK) equipped with an air-cooled argon--krypton mixed gas laser and mounted on to an Axiophote microscope (Zeiss, Sliedrecht, the Netherlands) using oil-immersion objectives (×40, numerical aperture \[NA\] = 3D1.3; or ×63, NA = 3D1.4). Cells incubated without the primary antibodies were used to determine non-specific background fluorescence.

**GLO-I assay** GLO-I activity was assayed by spectrophotometry according to the method of McLellan and Thornalley, monitoring the increase in absorbance at 240 nm due to the formation of *S*-[d]{.smallcaps}-lactoylglutathione for 10 min at 25°C \[[@CR31]\].

**Oxidative stress measurement** Reactive oxygen species were measured with the 5-(and-6-)-chloromethyl-2′7′-dichlorodihydrofluorescein diacetate acetyl ester (CM-H~2~DCFDA) assay (Invitrogen). In brief, endothelial cells cultured in black 96 wells (Cellstar; Greiner, Monroe, NC, USA) were loaded with 50 µmol/l CM-H~2~DCFDA for 45 min. Subsequently, cells were incubated with 1.0 mmol/l methylglyoxal (with or without 100 µmol/l *N*-acetyl-[l]{.smallcaps}-cysteine \[NAC\], 10 nmol/l EUK-134 and 10 nmol/l Mn\[III\]TMP pre-treatment), with simultaneous fluorescent signal (485/516 nm) measurement by micro-plate reader (Synergy Biotek, Winooski, VT, USA) during 60 min. Results are shown as arbitrary units (normalised fluorescent signal produced during 60 min) ± SEM.

**Cell viability assay** To assess cell viability, a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT; Invitrogen) assay was used. Briefly, endothelial cells were seeded at a density of 1 × 10^4^ cells per well into 96-well culture plates. Confluent monolayers were then exposed to various methylglyoxal concentrations (0.1, 0.33 and 1.0 mmol/l) for 60 min. Afterwards cells were incubated with MTT for 3 h and lysed with hydrogen chloride/isopropanol. Subsequently absorbance was measured at 570 nm and at 690 nm for background subtraction.

**NO measurement** Deoxygenated water was spiked with •NO gas and the •NO concentration was monitored with an Iso-NO meter (World Precision Instruments, Sarasota, FL, USA) at 37°C and the decrease in •NO concentration followed in time in the presence or absence of the test compound in solution (for details, see [ESM](#AppESM1){ref-type="sec"}).

**Statistical analysis** All values are expressed as mean ± SEM. Sensitivity (pD~2~) and maximum response (*E*~max~) were calculated from the concentration--response curves to acetylcholine. pD~2~ was defined as the negative logarithm to base 10 of the EC~50~ values and *E*~max~ was defined as the maximal vasorelaxation to acetylcholine at the highest concentration used and expressed as 100 minus percentage relative contractions to 65 mmol/l K^+^. The statistical differences in potency and maximum response between groups was tested using one-way ANOVA and the shift of the dose--response curve was tested with two-way ANOVA with a post hoc Bonferroni correction. A *p* value of less than 0.05 was considered statistically significant.

Results {#Sec3}
=======

**Hyperglycaemia-induced impairment of NO-mediated relaxation in rat mesenteric arteries is normalised by GLO-I overexpression** To investigate the effects of high glucose on vascular reactivity, isolated mesenteric arteries were mounted in a myograph and exposed to 30 and 40 mmol/l glucose for 2 h. Endothelium-dependent NO-mediated relaxation was tested in these arteries during precontraction with high potassium (65 mmol/l) in the presence of 10 µmol/l indometacin. High glucose did not lead to any alterations in precontraction (active wall tension in response to 65 mmol/l potassium was 2.8 ± 0.6 N/m). Pre-incubation with 30 or 40 mmol/l glucose reduced acetylcholine-induced vasorelaxation (Fig. [1a](#Fig1){ref-type="fig"}). The efficacy significantly decreased (*E*~max~ in presence of 5, 30 and 40 mmol/l glucose was 67 ± 2, 56 ± 3 and 50 ± 3% vasorelaxation, respectively; *p* \< 0.01), but the potency of acetylcholine was not altered (pD~2~ in presence of 5, 30 and 40 mmol/l glucose 6.6 ± 0.1, 6.7 ± 0.1 and 6.5 ± 0.1, respectively). This effect of glucose was not due to changes in osmotic values as indicated by normal relaxing responses to the osmotic control mannitol (*E*~max~ 65 ± 3%, pD~2~ 6.7 ± 0.1). The effect of high glucose was strictly endothelium-dependent, because no alterations in endothelium-independent relaxation were provoked with the NO-donor SNP (Fig. [1b](#Fig1){ref-type="fig"}). Fig. 1Effect of high glucose concentration on acetylcholine (ACh)-induced NO-mediated endothelium-dependent relaxation in isolated rat mesenteric arteries. **a** Rat mesenteric arteries were mounted in a myograph and incubated with or without high glucose concentrations for 2 h. Acetylcholine-induced NO-mediated endothelium-dependent relaxation was impaired in a concentration-dependent manner during incubation with 30 mmol/l glucose (white circles) or 40 mmol/l glucose (black circles) compared with control (5 mmol/l glucose, white squares). The 40 mmol/l glucose incubation resulted in a statistically significant shift of the dose--response curve (\**p* \< 0.05 vs control group). Incubation with 35 mmol/l mannitol (black squares) as an osmotic control did not impair NO-mediated endothelium-dependent relaxation (*n* = 6). **b** SNP-induced NO-mediated endothelium-independent vasorelaxation during incubation without (white squares) or with 40 mmol/l glucose (black circles) for 2 h did not differ (*n* = 6). **c** GLO-I activity in mesenteric arteries homogenates of *GLO-I* transgenic (TG) rats was significantly elevated compared with mesenteric arteries homogenates of wild-type rats (\*\*\**p* \< 0.001, *n* = 4). **d** In mesenteric arteries of *GLO-I* transgenic rats, acetylcholine-induced NO-mediated endothelium-dependent relaxation was not impaired during incubation with 40 mmol/l glucose (black circles) for 2 h compared with control incubations (5 mmol/l glucose, white squares, *n* = 5). **e** Acetylcholine-induced vasorelaxation was significantly impaired in wild-type diabetic rats (black squares; \**p* \< 0.05) compared with the controls (wild-type control, white squares; transgenic control, white circles). *GLO-I* overexpression improved this relaxation (black circles; *n* = 8). **f** The decreased potency in wild-type (WT) diabetic rats (\*\**p* \< 0.01) was significantly improved by *GLO-I* overexpression (\**p* \< 0.05)To study whether intracellular accumulation of methylglyoxal is involved in high glucose-induced impairment of acetylcholine-induced vasorelaxation, mesenteric arteries of rats with transgenic overexpression of the cytosolic GLO-I enzyme were used. In these transgenic rats we measured a significant increase (*p* \< 0.001) in GLO-I activity in the mesenteric arteries compared with their wild-type littermates (Fig. [1c](#Fig1){ref-type="fig"}). *GLO-I* overexpression prevented high glucose-induced impairment of endothelium-dependent NO-mediated relaxation (Fig. [1d](#Fig1){ref-type="fig"}), indicating that methylglyoxal is involved in high glucose-induced impairment of vasorelaxation. To test whether methylglyoxal is also involved in hyperglycaemia-induced impairment of vascular reactivity in vivo, we tested acetylcholine-induced vasorelaxation in the mesenteric arteries of wild-type and transgenic *GLO-I* rats with or without diabetes. Wild-type diabetic rats had decreased vascular reactivity to acetylcholine (and not to SNP; data not shown), which was improved by *GLO-I* overexpression (Fig. [1e](#Fig1){ref-type="fig"}). The potency of acetylcholine in the mesenteric arteries was markedly decreased in wild-type diabetic rats and significantly improved by *GLO-I* overexpression in transgenic rats (Fig. [1f](#Fig1){ref-type="fig"}).

**Extracellularly added methylglyoxal-derived AGEs do not lead to impaired vasoreactivity** To test a possible extracellular contribution of methylglyoxal-derived AGEs to vascular reactivity, methylglyoxal-modified albumin was added to the mesenteric arteries. Minimally and highly modified methylglyoxal-albumin was prepared by incubating albumin with 0.5 and 10 mmol/l methylglyoxal respectively for 2, 4 or 8 days. Concentrations of the AGEs CML, CEL and MG-H1 in the albumin preparations incubated for 2 days are shown in Fig. [2a--c](#Fig2){ref-type="fig"}. None of these methylglyoxal-albumin preparations modified contractile responses or acetylcholine-induced vasorelaxation in rat mesenteric resistance arteries, demonstrating that vasoreactivity is not functionally impaired by extracellular methylglyoxal-modified albumin adducts (Fig. [2d](#Fig2){ref-type="fig"}). Also albumin modified with methylglyoxal for 4 or 8 days did not affect reactivity compared with control albumin (data not shown). In contrast, under the same experimental conditions, the RAGE ligand S100b significantly (*p* \< 0.01) reduced acetylcholine-induced NO-mediated vasorelaxation in a dose-dependent manner (Fig. [2e](#Fig2){ref-type="fig"}). Fig. 2Effect of methylglyoxal-modified albumin and S100b on acetylcholine-induced NO-mediated endothelium-dependent relaxation in isolated rat mesenteric arteries. **a--c** Characteristics of methylglyoxal-modified albumin (MMA). Control albumin (CA) was exposed to methylglyoxal (0.5 and 10 mmol/l) for 2 days to prepare minimally modified methylglyoxal-albumin and highly modified methylglyoxal-albumin (HMA). The amount of CML (**a**), CEL (**b**) and MG-H1 (**c**) was determined by UPLC-MSMS analysis. **d** Acetylcholine (ACh)-induced NO-mediated endothelium-dependent relaxation during incubation with albumin (black squares), minimally modified methylglyoxal-albumin (white circles) and highly modified methylglyoxal-albumin (black circles) did not statistically differ from the control group (white squares); *n* = 4. **e** Incubation of mesenteric arteries with 20 (white circles) or 40 µg/ml (black circles) of the RAGE ligand S100b resulted in concentration-dependent impairment of acetylcholine-induced NO-mediated endothelium-dependent relaxation. The 40 µg/ml incubation resulted in a statistically significant shift of the dose--response curve; \**p* \< 0.05 vs control group, *n* = 4

**Methylglyoxal leads to impaired endothelium-dependent vasorelaxation** To determine the direct effect of methylglyoxal on vasoreactivity, rat mesenteric resistance arteries were exposed to methylglyoxal. The average isometric tension generated by the vessels during precontraction with high potassium (65 mmol/l) was 3.1 ± 0.5 N/m and did not significantly differ between the various incubations. Preincubation of the arteries with methylglyoxal significantly reduced acetylcholine-induced vasorelaxation in the presence of 10 µmol/l indometacin in a concentration-dependent manner (Fig. [3a](#Fig3){ref-type="fig"}), as indicated by a significantly decreased efficacy (*E*~max~ in presence of 0, 0.1, 0.33 and 1.0 mmol/l methylglyoxal 62 ± 3, 57 ± 1, 48 ± 3 and 39 ± 3%, respectively; *p* \< 0.001). In contrast, the potency of acetylcholine was not altered (pD~2~ in presence of 0, 0.1, 0.33 and 1.0 mmol/l methylglyoxal 6.5 ± 0.1, 6.3 ± 0.1, 6.2 ± 0.1 and 6.3 ± 0.2, respectively). Longer incubations with lower amounts of methylglyoxal (10 and 50 µmol/l for 2 h) also impaired NO-mediated vasorelaxation as indicated by decreased efficacy (*E*~max~ in presence of 0, 10 and 50 µmol/l methylglyoxal 58 ± 2, 55 ± 2 and 46 ± 3%, respectively; *p* \< 0.01; Fig. [3b](#Fig3){ref-type="fig"}). The impairment of acetylcholine-induced vasorelaxation by methylglyoxal was endothelium-dependent, as indicated by normal relaxing responses of arteries pre-incubated with methylglyoxal to the endothelium-independent NO donor SNP (Fig. [3c](#Fig3){ref-type="fig"}). Fig. 3Effect of methylglyoxal on vascular reactivity and intracellular MG-H1 formation. **a** Incubation of isolated mesenteric arteries for 1 h with 0.1 mmol/l (black squares), 0.33 mmol/l (white circles) and 1.0 mmol/l (black circles) methylglyoxal resulted in impairment of acetylcholine (ACh)-induced NO-mediated endothelium-dependent relaxation compared with the control group (white squares); *n* = 5 for all conditions. Incubation with 0.33 mmol/l and 1.0 mmol/l methylglyoxal resulted in a statistically significant shift of the dose--response curve (\**p* \< 0.05 and \*\*\**p* \< 0.001 respectively vs control group; *n* = 5). **b** Incubation of isolated mesenteric arteries for 2 h with 10 µmol/l (black squares) and 50 µmol/l (black circles) methylglyoxal resulted in impairment of acetylcholine-induced NO-mediated endothelium-dependent relaxation compared with the control group (white squares); *n* = 4 for all conditions. Incubation with 50 µmol/l methylglyoxal resulted in a statistically significant shift of the dose--response curve (\*\**p* \< 0.01 vs control group; *n* = 4). **c** SNP-induced NO-mediated endothelium-independent vasorelaxation during incubation without (white squares) or with 1.0 mmol/l methylglyoxal (black circles) for 1 h did not differ (*n* = 4). **d--i** Localisation of MG-H1 in adventitia and endothelial cells of mesenteric arteries not incubated (**d**) or incubated with 0.1 mmol/l (**e**), 0.33 mmol/l (**f**) or 1.0 mmol/l (**g**) methylglyoxal for 1 h. Intracellular localisation of MG-H1 was also determined by confocal laser scanning microscopy in cultured endothelial cells (ECRF24) incubated without (**h**) or with 1.0 mmol/l methylglyoxal (**i**) for 1 h. **j** Quantification of MG-H1 staining in arteries exposed to methylglyoxal (*n* = 4). **k** Concentration-dependent increase of MG-H1 levels in protein lysates of mesenteric arteries not incubated (Control) or incubated with 0.1, 0.33 or 1.0 mmol/l methylglyoxal (MGO) for 1 h as determined by UPLC-MSMS (*n* = 3). **j**, **k** \*\**p* \< 0.01 and \*\*\**p* \< 0.001 vs control group. AU, arbitrary units

Exposure of the mesenteric arteries to methylglyoxal leads to accumulation of the major methylglyoxal-derived AGE, MG-H1, which was predominantly localised in the adventitia and the endothelium (Fig. [3d--g](#Fig3){ref-type="fig"}). To confirm the accumulation of MG-H1 by methylglyoxal treatment and to further address the localisation of MG-H1 in endothelial cells, we incubated endothelial cells with methylglyoxal and showed intracellular localisation of MG-H1 predominantly in the cytoplasm and the nucleus of these endothelial cells (Fig. [3i](#Fig3){ref-type="fig"}). MG-H1 accumulation of methylglyoxal in mesenteric arteries was concentration-dependent as indicated by quantification of immunostaining of MG-H1 (Fig. [3j](#Fig3){ref-type="fig"}) and by UPLC-MSMS (Fig. [3k](#Fig3){ref-type="fig"}). These experiments demonstrated that extracellularly added methylglyoxal results in intracellular accumulation of MG-H1.

**Intracellular effects of methylglyoxal contribute to methylglyoxal-induced impairment of endothelium-dependent vasorelaxation** To study whether the intracellular accumulation of methylglyoxal and/or MG-H1 is involved in methylglyoxal-induced impairment of acetylcholine-induced vasorelaxation, arteries of *GLO-I* transgenic rats were incubated with 1.0 mmol/l methylglyoxal. These arteries did not show elevated MG-H1 levels, while methylglyoxal-incubated arteries of wild-type rats did (Fig. [4a--d](#Fig4){ref-type="fig"}). Furthermore, the impaired vasoreactivity of methylglyoxal-incubated mesenteric arteries of rats was normalised by *GLO-I* overexpression (Fig. [4e](#Fig4){ref-type="fig"}), indicating that extracellularly added methylglyoxal leads to intracellular processes that contribute to methylglyoxal-impaired endothelium-dependent vasorelaxation. Fig. 4Effect of *GLO-I* overexpression on methylglyoxal (MGO)-induced formation of the major methylglyoxal-adduct MG-H1 and on vascular reactivity. **a--d** Compared with MG-H1 staining in mesenteric arteries of wild-type rats incubated without (**a**) and with 1.0 mmol/l methylglyoxal (**b**), incubation for 1 h with 1.0 mmol/l methylglyoxal did not lead to intracellular MG-H1 formation in *GLO-I* transgenic rats incubated without (**c**) and with 1.0 mmol/l methylglyoxal (**d**). **e** In mesenteric arteries of *GLO-I* transgenic rats, acetylcholine (ACh)-induced NO-mediated endothelium-dependent relaxation was not impaired during incubation with 1.0 mmol/l methylglyoxal (black circles) for 1 h compared with control incubation (white squares) (*n* = 4)

**Methylglyoxal incubation leads to increased peroxynitrite via formation of reactive oxygen species** To investigate a possible role of ROS in the impairment of acetylcholine-induced vasorelaxation by methylglyoxal, we stained rat mesenteric arteries for nitrotyrosine after exposure to the endothelial nitric oxide synthase (eNOS) stimulus acetylcholine (Fig. [5a--d](#Fig5){ref-type="fig"}). Nitrosylation of tyrosine residues is a well-known marker for peroxynitrite formation, an oxidant product of NO. In parallel to MG-H1 accumulation, we observed that methylglyoxal resulted in an increase in nitrotyrosine staining in the same dose-dependent manner (Fig. [5e](#Fig5){ref-type="fig"}). This staining was not limited to specific regions of the vessel wall. Methylglyoxal-induced peroxynitrite formation was inhibited by treatment of the arteries with the NOS blocker [l]{.smallcaps}-NAME (data not shown). Fig. 5Methylglyoxal (MGO)-induced oxidative stress formation in isolated mesenteric arteries and cultured endothelial cells, and direct quenching of NO. **a--d** Representive staining of nitrotyrosine (NT) in mesenteric resistance arteries not incubated (**a**) or incubated for 1 h with 0.1 mmol/l (**b**), 0.33 mmol/l (**c**) or 1.0 mmol/l (**d**) methylglyoxal. **e** Quantification of NT staining in methylglyoxal-incubated arteries (*n* = 4). **f** Oxidative stress formation in endothelial cells as measured with a CM-H~2~DCFDA probe during treatment for 1 h with methylglyoxal as shown; *n* = 3. **g** Direct effect of methylglyoxal (MGO) and methylglyoxal-modified human albumin (HAS-MGO) on NO as measured with an Iso-NO meter in deoxygenated buffer. \**p* \< 0.05 and \*\*\**p* \< 0.001 vs control group. AU, arbitrary unitsTo confirm that methylglyoxal contributes to ROS production in the endothelium, we used a fluorescent probe in endothelial cells to monitor ROS production. In CM-H~2~DCFDA-loaded endothelial cells, methylglyoxal treatment resulted in a concentration-dependent increase in oxidative stress formation (Fig. [5f](#Fig5){ref-type="fig"}). Direct incubation of the DCF probe with methylglyoxal did not lead to any increase in fluorescent signal, thereby excluding a non-specific methylglyoxal effect (data not shown). To exclude possible cytotoxic effects of methylglyoxal on the endothelial cells, we performed a cell viability assay. The MTT assay showed no significant levels of cytotoxicity after 1 h treatment with 0.1, 0.33 and 1.0 mmol/l methylglyoxal (100 ± 4%, 98 ± 3% and 97 ± 5% viability compared with control cells, respectively). In addition, eNOS staining of the mesenteric arteries also showed that the endothelial cell layer remained intact after exposure to 1.0 mmol/l methylglyoxal. There were no signs of apoptosis as indicated by absence in the staining of the apoptotic marker cleaved caspase-3 (data not shown).We also investigated whether free methylglyoxal or methylglyoxal-derived AGEs have a direct effect on NO. Free methylglyoxal, but not highly modified methylglyoxal-albumin, did lead to increased breakdown of NO (Fig. [5g](#Fig5){ref-type="fig"}). Under the conditions used, the reaction between methylglyoxal and NO could be fitted according to a (pseudo) first-order reaction (log *k* = 1.05 ± 0.13 mol l^−1^ s^−1^). The results show that methylglyoxal reduced the half-life of NO in buffer from 4.3 ± 0.1 min to approximately 0.8 ± 0.2 min. In comparison, under the same experimental conditions, the rate constant found for the potent NO-quenching molecule haemoglobin was 1.0 × 10^4^ mol l^−1^ s^−1^ \[[@CR32]\].

**Antioxidant treatment prevents impaired vasorelaxation by methylglyoxal** The results so far suggest a reduction of NO bioavailability by methylglyoxal via induction of ROS formation. In line with this, pre-incubation of the mesenteric arteries with the antioxidants EUK-134, Mn(III)TMP and NAC prevented methylglyoxal impairment of acetylcholine-induced vasorelaxation (Fig. [6a](#Fig6){ref-type="fig"}). In addition, preincubation with the NAD(P)H oxidase inhibitor apocynin prevented decreased vascular relaxation (ESM Fig. [1](#MOESM2){ref-type=""}).Vessels incubated with antioxidants showed less nitrotyrosine staining upon incubation with 1.0 mmol/l methylglyoxal (Fig. [6b--f, g](#Fig6){ref-type="fig"}), but MG-H1 levels were not altered (Fig. [6h](#Fig6){ref-type="fig"}). In accordance, in cultured endothelial cells, the antioxidants also led to reduction of methylglyoxal-induced oxidative stress as measured with the CM-H~2~DCFDA probe (Fig. [6i](#Fig6){ref-type="fig"}). Fig. 6Effect of antioxidants on the effect of methylglyoxal on vascular reactivity and oxidative stress formation. **a** Acetylcholine (ACh)-induced NO-mediated endothelium-dependent relaxation during incubation without (white squares) or with 1.0 mmol/l methylglyoxal (black circles) for 1 h with or without pre-incubation for 20 min with the antioxidants NAC (1.0 mmol/l) (white diamonds), EUK-134 (1 µmol/l) (black squares) or Mn(III)TMP (1 µmol/l) (white circles). Treatment of mesenteric arteries with 1.0 mmol/l methylglyoxal in the absence of antioxidant resulted in a significant shift in the dose-response curve compared with the control group (\*\*\**p* \< 0.001). All antioxidant pretreatments prevented methylglyoxal-induced impairment of reactivity (*n* = 5). **b--f** Nitrotyrosine staining of arteries incubated without (**b**), or with 1.0 mmol/l methylglyoxal (**c**) and after pre-incubation with 1.0 mmol/l NAC (**d**), 1 µmol/l EUK-134 (**e**) or 1 µmol/l Mn(III)TMP (**f**). **g** Quantification of NT staining in mesenteric arteries after treatment with 1.0 mmol/l methylglyoxal (MGO) without or with pre-incubation NAC, EUK-134 or Mn(III)TMP (*n* = 4). **h** Quantification of MG-H1 staining in mesenteric arteries after treatment with 1.0 mmol/l methylglyoxal without or with pre-incubation at the same concentrations of NAC, EUK-134 or Mn(III)TMP. **i** Oxidative stress formation measured with a CM-H~2~DCFDA probe in ECRF24 cells after treatment with 1.0 mmol/l methylglyoxal without or with pre-incubation at 100 µmol/l NAC, 10 nmol/l EUK-134 and 10 nmol/l Mn(III)TMP (*n* = 3). **g--i** \*\*\**p* \< 0.001 vs control group; †*p* \< 0.001 vs methylglyoxal group. AU, arbitrary units

Discussion {#Sec4}
==========

In this study we have shown that hyperglycaemia-induced impairment of endothelium-dependent NO-mediated vasorelaxation of mesenteric arteries is mediated by the major AGE precursor methylglyoxal. The effect of methylglyoxal occurs intracellularly and is most likely to be caused by decreased bioavailability of NO due to a methylglyoxal-induced increase of oxidative stress. These data provide a mechanistic link between hyperglycaemia, the formation of the AGE precursor methylglyoxal and vascular complications.

Endothelial dysfunction is characterised by impaired vascular response to endothelium-derived NO and is associated with the development of micro- and macrovascular complications in diabetes \[[@CR33]\]. To gain insight into the mechanism by which hyperglycaemia alters endothelial function, we used acetylcholine, which stimulates the release of NO from endothelial cells, leading to relaxation of the underlying smooth muscle cells. Experiments were performed in the presence of indometacin and elevated K^+^ concentration to rule out involvement of endothelium-derived prostaglandins and hyperpolarising factors, and thus to focus on NO-mediated relaxation. Treatment of arteries with high concentrations of glucose significantly decreased acetylcholine-induced NO-mediated vasorelaxation (Fig. [1](#Fig1){ref-type="fig"}), which is in agreement with a previous study performed in mesenteric arteries \[[@CR34]\]. We also found that the effect of high glucose was prevented in arteries with *GLO-I* overexpression and that the impaired relaxation in diabetic rats was improved by *GLO-I* overexpression. In addition, incubation with exogenous methylglyoxal resulted in dose-dependent impairment of acetylcholine-induced vasorelaxation (Fig. [3](#Fig3){ref-type="fig"}). These data from ex vivo and in vivo experiments provide strong evidence that the impairment of endothelium-dependent NO-mediated vasorelaxation in diabetes is mediated by the major AGE precursor methylglyoxal.

Since the arterial contractile responses to K^+^ and relaxing responses to the NO-donor SNP were not modified by methylglyoxal, our data indicate that short exposure to methylglyoxal leads to an endothelium-dependent effect on vasorelaxation without a direct effect of methylglyoxal on arterial smooth muscle function. In accordance, Mukohda et al. showed that methylglyoxal had no effects on K^+^-induced contraction \[[@CR35]\]. Although not tested in our study, chronic exposure to exogenous methylglyoxal may also lead to impaired endothelium-independent vasorelaxation \[[@CR36]\].

We did not find any effects of extracellularly added methylglyoxal-modified albumin on vascular reactivity (Fig. [2](#Fig2){ref-type="fig"}). In accordance with this result, we had previously demonstrated that there is also no binding and biological effect of methylglyoxal-modified albumin on endothelial cells \[[@CR37]\]. In contrast, Xu et al. \[[@CR11]\] showed that other extracellularly formed AGEs can impair endothelium-dependent vasorelaxation, but these data were obtained with AGE-albumin, which was prepared with a degree of modification that is much higher than that ever seen in diabetes. A recent paper by Gao et al. \[[@CR38]\] described the importance of S100b-induced RAGE activation in endothelial dysfunction and impaired vasoreactivity. We confirmed the finding that the RAGE ligand S100b reduces acetylcholine-induced NO-mediated vasorelaxation (Fig. [2e](#Fig2){ref-type="fig"}). Combined, these data provide strong evidence that extracellular methylglyoxal-derived AGEs are not involved in diabetic arterial dysfunction and that other ligands for RAGE, such as CML and S100b, impair endothelium-dependent vasorelaxation.

Another important finding of our study is that the effect of hyperglycaemia and methylglyoxal on NO-mediated vasorelaxation in rat mesenteric arteries is completely abolished in rat mesenteric arteries with overexpression of *GLO-I*, indicating that the effect of hyperglycaemia and exogenous methylglyoxal is due to intracellular effects of methylglyoxal in endothelial cells. We recently found that endothelial cells incubated with high glucose concentrations display an increase in methylglyoxal \[[@CR18]\] and we have now demonstrated that methylglyoxal leads to intracellular accumulation of the major methylglyoxal-induced AGE, MG-H1. This is in agreement with a study showing that methylglyoxal, given intraperitoneally to rats for 7 weeks, induces an increase in vascular AGE content \[[@CR36]\]. In our study, MG-H1 appeared to be localised in the cytoplasm and in the nucleus of endothelial cells. The latter is in accordance with data of two recent papers about methylglyoxal modification of nuclear proteins \[[@CR39], [@CR40]\]. Furthermore, Schlotterer et al. \[[@CR41]\] recently reported that hyperglycaemia leads to methylglyoxal-modified mitochondrial proteins and reduced lifespan in *C. elegans.* This oxidative stress-dependent process was inhibited by *GLO-I* overexpression, thereby linking methylglyoxal to the formation of ROS.

Chronic hyperglycaemia is associated with increased intracellular levels of methylglyoxal \[[@CR18], [@CR42]\], oxidative stress \[[@CR43], [@CR44]\] and an impairment of NO synthesis pathways \[[@CR45]\]. Our results link these studies by showing an oxidative stress-dependent effect of methylglyoxal on NO bioavailability. This impairment was prevented by superoxide dismutase mimetics and by the antioxidant NAC (Fig. [6](#Fig6){ref-type="fig"}). Moreover, the impaired relaxation could also be prevented by apocynin, but because of the lack of specificity of this NAD(P)H inhibitor \[[@CR46]\], the exact mechanism by which methylglyoxal induces the formation of ROS is not completely clear. Although not addressed in this study, methylglyoxal modifications of mitochondrial membrane proteins \[[@CR27]\], antioxidant enzymes \[[@CR47]\] and GAPDH \[[@CR48]\] may increase oxidative stress and, as a consequence, impair endothelium-dependent vasorelaxation.

Because AGEs are known to inactivate NO by a direct chemical reaction, the impaired endothelium-dependent vasodilatation in diabetes may be mediated by NO quenching and NO depletion by methylglyoxal-derived AGE accumulation \[[@CR49]\]. Indeed, we observed quenching of NO by methylglyoxal, but not by methylglyoxal-derived AGEs. Methylglyoxal reduced the half-life of NO in buffer from 4 to approximately 1 min. However, in vivo the very fast reaction of NO with numerous bio-molecules, such as haemoglobin, is one of the reasons why the half-life of NO in biological systems is very short, i.e. less than 1 s \[[@CR50]\], and not susceptible to being shortened by methylglyoxal. Therefore, the physiological relevance of quenching of NO by methylglyoxal, for example in methylglyoxal-induced impairment of endothelium-dependent vasodilatation, is very limited. Methylglyoxal and methylglyoxal-derived AGEs may also decrease NO availability by decreasing NO synthase activity, but in our previous study we already ruled out the possibility that free methylglyoxal and the methylglyoxal-derived AGEs argpyrimidine and MG-H1, which have some structural homology with the NOS inhibitor asymmetric dimethylarginine, directly inhibit eNOS activity \[[@CR51]\]. Together, these findings indicate that the effects of methylglyoxal on vasoreactivity are thus caused by methylglyoxal-induced oxidative stress and the quenching of NO by oxidative stress, rather than direct interaction of methylglyoxal-adducts with NO or eNOS activity. The question of whether methylglyoxal or methylglyoxal-induced AGEs are involved in impaired eNOS activation by oxidative-stress-related interference with eNOS phosphorylation needs to be further investigated.

For the ex vivo and in vitro experiments, we used methylglyoxal in a range of 10 to 1,000 µmol/l, a range that caused effects in a concentration-dependent manner. The in vivo concentration of methylglyoxal is under debate; plasma methylglyoxal levels are estimated to be about 0.5 µmol/l in healthy individuals and can increase twofold in diabetes \[[@CR52]\], while others have demonstrated that plasma methylglyoxal concentration in poorly controlled human diabetic patients is about 400 µmol/l \[[@CR53]\]. Nevertheless, cells produce large amounts of methylglyoxal \[[@CR54]\] and therefore intracellular levels are probably much higher than plasma levels \[[@CR55]\]. Although the maximum concentration of methylglyoxal used in the present study appears to be higher than levels observed in vivo, this concentration was also used to increase intracellular concentrations and to mimic life time exposure to elevated levels of methylglyoxal such as in diabetes and in hypertension. Under our experimental conditions, exposure to elevated methylglyoxal levels did not lead to cytotoxic effects.

What are the clinical implications of these observations? Because higher plasma levels of methylglyoxal have been demonstrated under postprandial conditions \[[@CR36]\] and in plasma of diabetic patients \[[@CR17]\], as well as in endothelial cells incubated with high glucose concentrations \[[@CR18], [@CR43]\], we propose here that methylglyoxal plays a crucial role in impaired endothelium-dependent vasorelaxation under postprandial conditions and in chronic hyperglycaemia, and in the long term in development of vascular complications.

In summary, we found that hyperglycaemia-induced impairment of endothelium-dependent NO-mediated vasorelaxation is prevented by *GLO-I* overexpression and that methylglyoxal decreased NO-mediated vasorelaxation due to an increase in oxidative stress. We conclude that hyperglycaemia-induced impairment of endothelium-dependent vasorelaxation is mediated by intracellular methylglyoxal levels in an oxidative stress-dependent pathway. These data provide a new mechanistic link between hyperglycaemia, the formation of methylglyoxal-derived AGEs and vascular complications.
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Inhibition of NAD(P)H oxidase normalises methylglyoxal-induced impaired NO-mediated relaxation. Acetylcholine (ACh)-induced NO-mediated endothelium-dependent relaxation during incubation without (white squares) or with (black circles) 1.0 mmol/l methylglyoxal, and with 1.0 mmol/l methylglyoxal after 20 min pre-treatment with 100 µmol/l apocynin (white circles). Preincubation with apocynin prevented the impairment of NO-mediated relaxation induced by 1.0 mmol/l methylglyoxal for 1 h (*p* \< 0.05; *n* = 5) (PDF 487 kb)
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